{
  "drug_name": "Temocillin",
  "usage_and_dosing": {
    "general_info": [
      "Temocillin is a 6-a-methoxy derivative of Ticarcillin (discontinued) with excellent stability in the presence of beta-lactamases from Gram-negative bacilli, including TEM, CTX-M and AmpC beta-lactamases. Stable against some metallo-beta-lactamases.",
      "The weakness of Temocillin is the lack of activity against anaerobic bacteria and P. aeruginosa. Good in vitro activity against B. cepacia.",
      "Outside of the USA, used in the treatment of susceptible bacteria causing:",
      "UTI",
      "Bacteremia",
      "Pneumonia",
      "For availability, contact Eumedica Pharmaceuticals (Belgium): www.eumedica.com, + 32 64 27 1738. Temocillin is not available in the U.S."
    ],
    "adult_dose": {
      "usual_dose_intermittent": "2 gm IV q12h",
      "critically_ill_patients": "2 gm IV q8h (See Continuous Infusion for alternative dosing approach)"
    },
    "pediatric_dose": [
      {
        "age": ">28 Days",
        "dose": "50 mg/kg/day (divided q12h)"
      }
    ],
    "renal_adjustment": {
      "half_life_hrs_renal_function_normal": 4,
      "half_life_hrs_esrd": "No data",
      "dose_renal_function_normal": "1-2 gm IV q12h",
      "crcl_or_egfr": [
        "CrCl >50: No dosing adjustment",
        "CrCl 30-50: 1-2 gm q24h",
        "CrCl 10-30: 1 gm q48h"
      ],
      "hemodialysis": "1 gm q48h (give AD on dialysis days)",
      "capd": "1 gm q48h",
      "crrt": "No data",
      "sled": "No data"
    },
    "hepatic_adjustment": "No dosage adjustment"
  },
  "adverse_effects": [
    "Maculopapular rash, C. difficile colitis reported."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "use_during_lactation": "No data"
  },
  "antimicrobial_spectrum": [
    "No activity against Gram-positive organisms, anaerobes or P. aeruginosa.",
    "Broadly active against aerobic Gram-negative bacilli, including organisms that produce AmpC and extended-spectrum beta-lactamases (ESBLs)."
  ],
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "pharmaceutical_preparations": "Injection",
    "peak_serum_conc_mcg_ml": "150-200 (2 gm IV, SD)",
    "protein_binding_percent": "70-85",
    "volume_of_distribution_vd": "0.2 L/kg",
    "avg_serum_t1_2_hr": 4,
    "elimination": "Renal",
    "bile_penetration_percent": "800-1000",
    "csf_blood_percent": "8-15",
    "auc_mcg_hr_ml": "785 (2 gm IV, 0-inf)"
  },
  "major_drug_interactions": "No significant interactions identified.",
  "comments": [
    "Good PK/PD review: Clin Pharmacokinet 57:287, 2018.",
    "Use as narrow spectrum therapy, see: Future Microbiol 14(2): 81, 2019"
  ]
}